Compare CMTG & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTG | AKBA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.8M | 248.3M |
| IPO Year | 2016 | 2014 |
| Metric | CMTG | AKBA |
|---|---|---|
| Price | $1.55 | $0.45 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $1.87 | ★ $3.00 |
| AVG Volume (30 Days) | 1.9M | ★ 8.7M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $187,828,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $0.36 |
| 52 Week High | $3.62 | $1.75 |
| Indicator | CMTG | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 35.11 |
| Support Level | $1.44 | $0.36 |
| Resistance Level | $1.65 | $1.54 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 50.00 | 19.62 |
Claros Mortgage Trust Inc is a real estate investment trust. The company is focused mainly on creating a diversified portfolio of income-producing loans collateralized by institutional-quality commercial real estate.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.